indones J Intern Med. 2005;37:126-131.
2. Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Clin Liver Dis. 1997;1:1-12.
3. Eyal A MD , Kovalev Y MD and Zuckerman E MD. Evaluation and Treatment of Esophageal Varices in the Cirrhotic Patient. IMAJ. 2013;15: 109-115.
4. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology. 2002;122:1620-1630 5. D’Amico G, Criscuoli V, Fili D, Mocciaro F, Pagliaro L. Metaanalysis of
trials for variceal bleeding. Hepatology. 2002;36:1023-1024
6. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–659
7. Chalasani, N., C. Kahi. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003;98(3):653–659
8. Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969–2002. Hepatology. 2006;43:500-505
9. Djojoningrat D. Hematemesis melena di bagian Ilmu penyakit dalam FK-UI/RSCM. Tesis Jakarta: Bagian Ilmu Penyakit Dalam FKUI, 1990
10.De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167-176
11.Dite P et al. Esophageal varices. World Gastroenterology Organisation practice guideline: June 2008
12.De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762-768
13.Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922-938.
15.D’Amico G, Pagliaro L, Bosch J. Treatment of portal hypertension: a meta-analytic review. Hepatology. 1995;22:332-54.
16.de Franchis R. Non-invasive (and minimally invasive) diagnosis of oesophageal varices. J Hepatol. 2008;49:520-527
17.Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59-68
18.Sebastiani G, Tempesta D, Fattovich G, et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum noninvasive markers: Results of a multicenter, large-scale study. J Hepatol. 2010;53:630-638
19.Sheng-di Wu, Yan-jun Ni, Li-li Liu. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patient with chronic hepatitis B. Hepatol Int. 2012;6:360-368
20.Cheney CP, Goldberg EM, Chopra S. Cirrhosis and portal hypertension: an overview. In: Friedman LS and Keeffe EB, eds.Handbook of Liver Disease. 2nd ed. China, Pa: Churchill Livingstone. 2012;125-138
21.Wolf DC. Cirrhosis of the Liver. eMedicine Specialities. 29 Nov 2012. Available at: http://www.emedicine.com/med/topic3183.htm
22.World Health Organization. Hepatitis C - global prevalence (update). Weekly Epidemiological Record. 1999;74:425-427
23.Suk TK. Revision and update on clinical practice guideline for liver cirrhosis. The Korean Journal of Hepatology. 2012;18:1-21
24.Bissell D, Maher JJ. Hepatic Fibrosis and Cirrhosis. In: Zakim D and Boyer TD, eds. Hepatolog. A Textbook of Liver Disease, vol 1, 3rd ed, Tokyo. 1996;506
25.Hernomo K. Pengelolaan perdarahan masif varises esofagus pada sirosis hati. Thesis. Airlangga University Press, Surabaya. 1983
26.Benvegnu L, Gios M, Bocato S et.al. Natural history of compensated viral cirrhosis a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-749
27.Garcia-Tsao D, Wongcharatrawee S. (VA Hepatitis C Resource Center Program). Treatment of patients with cirrhosis and portal hypertension literature review and summary of recommended interventions. Version 1 (October 2003). Available at: www.va.gov/hepatitisc
28.Friedman SL, Hepatic Fibrosis. In : Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. 9th ed. Philadelphia, Pa: Lippincott-Raven. 2003;409-28
30.Erlingen S, Benhamou JP. Cirrhosis : clinical aspect. In: Oxford Textbook of Clinical Hepatology, Vol 1, 2nd ed.Hong Kong, Pa: Oxford Medical Publications. 1999;629-644
31.Sharara AI, Rockey DC. Gastroesophageal Variceal Hemoorhage. N Engl J Med. 2001;345:669-681
32.Sanyal A, Bosch J, Blei A, Arroyo V, Portal Hypertension and its complication. Gastroenterology. 2008;134:1715–1728.
33.R. de Franchis, Stellate cells and the “reversible component” of portal hypertension, Digestive and Liver Disease. 2000;32(2):104–107
34.Y. Iwakiri and R. J. Groszmann, Vascular endothelial dysfunction in cirrhosis, Journal of Hepatology. 2007;46(5);927–934.
35.D. C. Rockey, Hepatic blood flow regulation by stellate cells in normal and injured liver, Seminars in Liver Disease. 2001;21(3):337–349
36.Wheatley AM , Zhang X - Y. Intrahepatic modulation of portal pressure and its role in portal hypertension . Digestion. 1998;59:424 – 428 .
37.M. Fernandez, M. Mejias, E. Garcia-Pras, R. Mendez, J. C. Garcia-Pagan, and J. Bosch, Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats, Hepatology. 2007; 46:1208–1217
38.Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing Portal Hypertension in liver diseases. Expert Rev. Gastroenterol. Hepatol. 2003;7(2):141–155 39.Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK,
Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R. B-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254-2261
40.Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488 41.D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. HVPG reduction and
prevention of variceal bleeding in cirrhosis. A systematic review. Gastroenterology. 2006;131:1624
42.D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies. J Hepatol. 2006;44:217-231
44.Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004;127:476–484
45.Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38:266–272 46.Bosch J et al. Portal Hypertension and Gastrointestinal Bleeding.
Seminars in liver disease. 2008;28(1)
47.De Franchis R. Evaluation and follow-up of patients with cirrhosis and oesophageal varices. J Hepatol. 2003;38:361–363
48.D’Amico G, de Franchis R. Upper digestive bleeding in cirrhosis: post -therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599– 612
49.Matsuo M, Kanematsu M, Kim T, Hori M, Takamura M, Murakami T,Kondo H, Moriyama N, Nakamura H, Hoshi H. Esophageal Varices:Diagnosis with Gadolinium-Enhanced MR Imaging of the Liver for Patients with Chronic Liver Damage. AJR. 2003;180:461-466.
50.Ishiguro H, Saito S, Imazu H, Aihara H, Kato T, Tajiri H. Esophageal Capsule Endoscopy for Screening Esophageal Varices among Japanese Patients with Liver Cirrhosis. Hindawi Publishing Corporation Gastroenterology Research and Practice. 2012;1-6.
51.Stefanescu H, M. Grigorescu, M. Lupsor, A. Maniu, A. Crisan, B. Procopet, D. Feier, R. Badea. A New and Simple Algorithm for the Noninvasive Assessment of Esophageal Varices in Cirrhotic Patients Using Serum Fibrosis Markers and Transient Elastography. J Gastrointestin Liver Dis. 2011;20(1):57-64.
52.Hsieh Y.Y, Tung S.Y, Lee K, Wu C.S, Wei K.L. Routine Blood Test to Predict Liver Fibrosis in Chronic Hepatitis C. World Journal of Gastroenterology. 2012;(18):746-753.
53.Mallet V , Vernier VD, Roussins C et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics. 2009;29:409-415.
54.Poynard T, Mathurin P, Lai CL, et al. A Comparison of Fibrosis progression in Chronic Liver Disease. J Hepatol. 2003;38:257-265.
55.Muljono DH, Kandun N, Gani RA, Hasan I, Oswari H. Pedoman Pengendalian Hepatitis Virus. Direktorat Jenderal PP&PL Kementerian Kesehatan RI. 2012:1-85.
57.Kujovich, J.L. 2005. Hemostatic defects in end stage liver disease. Crit Care Clin. 2005;21:563-587
58.Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006:Vi1-Vi12
59.Kujovich, J.L. 2005. Hemostatic defects in end stage liver disease. Crit Care Clin. 2005;21:563-587
60.Martinez RG, Caraceni P, Bernardi M, Gines P, Arroya V, Jalan R. Albumin: Pathophysiologic Basic of its role in the Treatment of Cirrhosis and its Complications. Hepatology. 2013;5:1836-1846.
61.Neelesh Despande, Sabitha Kandi, et al. A Study of Boichemical and Hematological Markers in Alcoholic Cirrhosis. World Journal of Nutrition and Health. 2014;2(2):24-27.
